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Supplemental Data 
Defining  the  in  vivo  role  for  cytochrome  b5  in  cytochrome  P450 
function through the conditional hepatic deletion of cytochrome b5
Robert D. Finn, Lesley A. McLaughlin, Sebastien Ronseaux, Ian Rosewell, J. Brian 
Houston, Colin J. Henderson and C. Roland Wolf. 
 
Supplemental Experimental Procedures 
HPLC separation for microsomal incubations  
HPLC analysis was carried out using a Hewlett Packard 1100 HPLC with UV 
detection and Chemstation software following the previously described conditions: 
bufuralol (1), chlorzoxazone (2).  Metabolites were quantified with reference to authentic 
metabolite standards. 
 
LC/MS-MS conditions for microsomal incubations 
Microsomal product formation from phenacetin, midazolam, metoprolol and 
tolbutamide was analyzed by LC-MS/MS (Waters 2795 HPLC and Quattro Micro mass 
spectrometry system). The capillary temperature and voltage were respectively set at 
250˚C, 3 kV in positive and 250˚C, 4 kV in negative electrospray ionization mode. 
Multiple reaction monitoring (MRM) data were acquired (Supplementary Table 1). 
Substrates, phenacetin, metoprolol and tolbutamide, were diverted in the waste. The cone 
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voltage and collision energy were optimized for each product (Supplementary Table 1); a 
dwell time of 0.5 s was used between MRM transitions. 
4-Hydroxy midazolam, 1′-hydroxy midazolam and the internal standard (IS) 
phenacetin were resolved in 5 min on a Luna C18 (2) (5 µ, 100 Å, 50 x 2.00 mm) column 
(Phenomenex, Torrance, CA).  The injection volume was 20 µl. The following elution 
program was used at a temperature of 30˚C and a flow rate of 0.5 ml/min: Eluent A – 
0.1% formic acid; Eluent B – Acetonitrile; (i) a linear gradient from 3% to 50% B was 
run in 3 min, (ii) mobile phase was held at 50% B for 0.5 min, (iii) linear gradient was 
run to 60% B in 0.5 min, (iv) solvent composition was returned to 3% B for equilibration.  
 Acetaminophen and the internal standard caffeine were resolved with a Luna C18 
(5 µ, 100 Å, 50 x 2.00 mm) column (Phenomenex, Torrance, CA) with a run time of 5 
min.  The injection volume was 5 µl. The following elution program was used at a 
temperature of 20˚C and a flow rate of 0.2 ml/min: 75% Eluent A – 20mM ammonium 
formic pH 2.6 and 25% Eluent B – Acetonitrile.  
 O-Desmethyl metoprolol, α-hydroxy metoprolol, metoprolol acid and the internal 
standard caffeine were analyzed with a Gemini C18 (5 µ, 110 Å, 50 x 2.00 mm) column 
(Phenomenex, Torrance, CA).  The injection volume was 20 µl. The following elution 
program was used at a temperature of 20˚C and a flow rate of 0.3 ml/min: Eluent A – 10 
mM ammonium formate pH 3.0; Eluent B – Acetonitrile wit 0.1 % formic acid;(i) mobile 
phase was held at 9% B for 2.5 min, (ii) a linear gradient from up to 95% B was run in 1 
min, (iii) mobile phase was held at 95% B for 2.5 min, (iv) solvent composition was 
returned to 9% B for equilibration.  
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4-Hydroxy tolbutamide and the internal standard chlorzoxazone were resolved 
using a Hypersil C18 (3 µ, 120 Å, 50 x 2.00 mm) column (Phenomenex, Torrance, CA). 
The injection volume was 50 µl.  The following elution program was used at a 
temperature of 20˚C and a flow rate of 0.25 ml/min: 55% Eluent A – 20mM ammonium 
formic pH 2.6 and 45% Eluent B – Methanol. 
 
LC/MS-MS conditions for blood samples 
Blood extracts were analyzed for chlorzoxazone, metoprolol, midazolam, 
phenacetin, tolbutamide and the two internal standards; caffeine and resorpine.  LC-
MS/MS was carried out using a Waters 2795 HPLC coupled to a Quattro Micro Mass 
spectrometry system (MicroMass, Manchester, United Kingdom) in the positive and 
negative electrospray ionization mode.  The capillary temperature and voltage were set as 
outlined above for the microsomal samples.  Multiple reaction monitoring (MRM) data 
were acquired for each substrate (Supplementary Table 2).  The cone voltage and 
collision energy was optimized for each compound (Supplementary Table 2); a dwell 
time of 0.1 s was used between MRM transitions. 
 Chromatography was carried out on a Luna C18 (2) (5µ, 100A, 50 x 2.00mm) 
column (Phenomenex, Torrance, CA), with an injection volume of 10 µl. The following 
elution program was used at a temperature of 20˚C and a flow rate of 0.4 ml/min: Eluent 
A – 20mM ammonium formic pH 2.6; Eluent B – Methanol; (i) mobile phase was held at 
15% B for 1 min, (ii) linear gradient was run to 75% B in 1 min, (iii) linear gradient was 
run to 90% B in 2 min, (iv) linear gradient was run to 95% in 0.5 min, (v) solvent 
composition was returned to 15% B for equilibration. 
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Reduced CO-difference spectra 
 P450 content of mouse liver microsomes was determined by P450 (Fe2+) - CO 
versus P450 (Fe2+) difference spectra from a sample of three pooled mouse livers as 
previously described (4). 
 
Recapitulation of P450 activity method 
 HBN liver microsomes (25μg) were mixed with increasing amounts of E.coli 
membranes containing recombinant murine cytochrome b5 (0-46 pmol of cytochrome b5).  
Eppendorf tubes were capped and incubated at room temperature for 20 min.  190 μl of 
100mM potassium phosphate buffer pH7.4 containing 30 μM BFC or 500 μM 
chlorzoxazone was then added and tubes mixed before placing into the wells of a 96 well 
plate.  Reactions were initiated with 10 µl of 10 mM NADPH and run for 3 min (BFC) or 
15 min (chlorzoxazone) at 37ºC and metabolites measured as previously described.  
Cytochrome b5 only and wild-type controls were also included. 
 
Lipid Analysis 
 Detailed fatty acid profile analysis was carried out on liver microsomes, prepared 
as outlined in Experimental procedures, by the Nutrition Analytical Service, University 
of Stirling, UK. 
For histology, liver samples were snap-frozen in Cryo-M-Bed (Bright Instrument 
Co, Huntington, UK), cryo-sectioned (10µM) and stained with Oil Red O (lipid content). 
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Supplemental Figure Legends 
Supplemental Figure 1: Generation of hepatic cytochrome b5 null mice. (A) Diagrams 
of the wild-type, targeted (floxed) and disrupted Cytb5 alleles. LoxP sites are indicated by 
triangles and the selectable marker (hsv-tk-neo) is indicated by a shaded box. The hatched 
box indicates the position of the probe used in Southern screening, and the numbered 
arrows indicate the position of the PCR primers used for screening, as detailed in the 
Experimental procedures. The dotted lines under the targeted (floxed) allele indicate the 
extent of DNA excision by Cre recombinase between the outermost loxP sites. (B) (i) 
Southern blot and (ii) PCR analysis of genomic DNA from Cytb5lox/+, Cytb5lox/lox and 
Cytb5+/+ mice. For Southern blotting, the wild-type allele is represented by a band at 15 
kb and the targeted (floxed) allele (Cytb5lox) containing the selectable marker by a band at 
11 kb. Note: the targeted allele arises from Ola 129 genomic DNA, and the band 
generated by restriction digest on a Southern blot is smaller due to the presence of an 
additional BglII site in intron 3, which is not present in the gene locus in the C57BL/6 
genome. For PCR analysis, the wild-type allele is represented by a band at 500 bp and the 
targeted allele (Cytb5lox) containing the selectable marker by a band at 900 bp. 
 
Supplemental Figure 2: (A) Reduced CO-difference spectra for HBN and wild-type 
(WT) liver microsomes and (B), (C) recapitulation of NADPH-mediated P450 activity 
towards BFC and chlorzoxazone, respectively, by supplementation of microsomes with 
exogenous cytochrome b5 (11.5, 23, 34.5 and 46 pmol respectively) carried out as 
described in Supplemental Experimental procedures.  Data is mean + SD. 
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Supplemental Figure 3: Lipid Analysis of HBN liver and microsomal membranes. (A) 
Hepatic lipid content was visualized by Oil red O staining of snap-frozen sections. 
Photomicrographs were taken at 10x magnification, bright field, and are representative of 
the results from at least three mice per group. (B) Fatty acid profile analysis of 
microsomal membranes (i) total lipid, (ii) saturated fatty acids and (iii) monounsaturated 
fatty acids. Black and white bars represent wild-type and HBN mice respectively. Data is 
expressed as a fold change compared to wild-type membranes. 
 
Supplemental Figure 4: Pharmacokinetic disposition of an orally administered P450 
drug cocktail in wild-type and hepatic microsomal cytochrome b5 null mice. A P450 drug 
cocktail containing chlorzoxazone (5mg/kg), metoprolol (2mg/kg), midazolam (5mg/kg), 
phenacetin (5mg/kg) and tolbutamide (5mg/kg) was administered orally to wild-type 
(black circles) or HBN (open circles) mice and blood samples taken at timed intervals to 
determination the in vivo pharmacokinetic parameters of the parent compounds. * = p ≤ 
0.05, ** = p ≤ 0.005, *** = p ≤ 0.001 where n = 3.  Insert A shows pharmacokinetic 
disposition of orally administered tolbutamide (5mg/kg) as a single agent to wild-type 
(black circles) or HBN (open circles) mice (n=2 wild-type and 4 HBN).   
 
Supplemental Figure 5: Measurement of metabolites for phenacetin (acetaminophen), 
metoprolol (O-desmethyl metoprolol) and midazolam (1′-hydroxy midazolam) from 
HBN (open circles) and wild-type (black circles) mice after intravenous (A) or oral (B) 
administration. 
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Supplementary Figure 5 
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Supplementary Table 1: Modes of detection and parameters used to quantify the 
different products formed during microsomal incubations with the LC-MS/MS. 
Drug  Ion 
mode 
MRM transitions  Cone 
voltage 
(V) 
Collision 
Energy  
(kV) 
4­Hydroxy tolbutamide  ‐ ve  285.1 > 186.1  32  21 
Chlorzoxazone (IS)  ‐ ve  168.2 > 131.9  44  25 
Acetaminophen  + ve  180.3 > 110.3  30  30 
4­Hydroxy midazolam  + ve  342.4 > 234.3  30  23 
1­Hydroxy midazolam  + ve  342.4 > 324.3  30  22 
O­Desmethyl metoprolol  + ve  254.1 > 177.2 
254.1 > 72.0 
35  20 
α­Hydroxy metoprolol  + ve  284.1 > 73.9 
284.1 > 116 
35  21 
Caffeine (IS)  + ve  195 > 138  35  25 
Phenacetin (IS)  + ve  180.3 > 110.3  30  30 
Resorpine  + ve  607.1 > 137  70  46 
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Supplementary  Table  2: Modes  of  detection  and  parameters  used  for  each 
individual drug measured by LC­MS/MS in plasma samples. 
Drug  Ion de  mo M sRM transition   Cone tage 
(V) 
 vol Collisio nergy 
(kV) 
n e
Tolbutamide  ‐ ve  269.1 > 170.2  30  20 
Chlorzoxazone  ‐ ve  168.1 > 131.9  44  25 
Resorpine (IS)  ‐ ve  607.1 > 137  70  46 
Phenacetin  + ve  180.3 > 110.3  30  30 
Midazolam  + ve  326.4 > 291.4  30  27 
Metoprolol  + ve  268 > 133  30  26 
affeine (IS)  + ve  195 > 138  35  25 C
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Supplementary Table 3: NADPH and NADH dependent P450 activities of wild-type and cytochrome b5 hepatic null 
microsomes towards a range of P450 model substrates 
Assays were performed in triplicate with liver microsomes at substrate concentrations approximately 5 times Km and turnover rates 
calculated by reference to authentic standards. 
 NADPH   NADH  
Substrate Metabolite 
WT rate 
(pmol/min/pmol)
HBN rate 
(pmol/min/pmol)
p value 
 WT rate 
(pmol/min/pmol)
HBN rate 
(pmol/min/pmol)
p value 
BFC HFC 362 ± 120 68 ± 33 0.0002  106 ± 101 0.7 ± 1.7 <0.0001
EFC HFC 464 ± 165 47 ± 30 <0.0001  88 ± 17 0.7 ± 1.0 <0.0001
MFC HFC 591 ± 183 64 ± 51 <0.0001  72 ± 18 0.2 ± 0.6 <0.0001
ER Resorufin         27 ± 5         20 ± 4 0.02          14 ± 3         10 ± 2 0.02 
BR Resorufin 22 ± 10 8 ± 2 0.007  0.9 ± 0.8        1.4 ± 1.0 0.35 
Bufuralol 1′-OH Bufuralol 670 ± 189       292 ± 26 0.0007        254 ± 76 72 ± 27 0.002 
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Supplementary Table 4: Summary of pharmacokinetic data on drugs administered  intravenously  to HBN mice and 
wild­type controls. 
Adult male HBN and WT mice (n =4) were administered a drug cocktail intravenously; serial blood samples were collected over a 8 
hour period and analysed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. 
Drug PK parameters WT HBN p-value 
AUC (0→∞) (min*µg/ml) 244 ± 63 224 ± 43 0.81 
AUC (0→480) (min*µg/ml) 241 ± 63 149 ± 16 0.26 
Clearance (ml/min/kg) 28 ± 8 24 ± 5 0.71 
Midazolam 
Terminal half-life (min) 83 ± 15   330 ± 132 0.03 
AUC (0→∞) (min*µg/ml) 522 ± 110 617 ± 85 0.52 
AUC (0→480) (min*µg/ml) 520 ± 110 524 ± 22 0.97 
Clearance (ml/min/kg) 12 ± 3 8.4 ± 1.1 0.34 
Phenacetin 
Terminal half-life (min) 53 ± 11 168 ± 56 0.02 
Metoprolol AUC (0→∞) (min*µg/ml) 76 ± 19   89 ± 14 0.61 
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AUC (0→480) (min*µg/ml) 75 ± 19 64 ± 5 0.66 
Clearance (ml/min/kg) 36 ± 10   24 ± 4.4 0.35 
 
Terminal half-life (min) 97 ± 14 261 ± 65 0.10 
AUC (0→∞) (min*µg/ml) 432 ± 74   663 ± 127 0.10 
AUC (0→480) (min*µg/ml) 420 ± 75 481 ± 39 0.52 
Clearance (ml/min/kg) 13 ± 2 8.2 ± 1.8 0.13 
Chlorzoxazone 
Terminal half-life (min) 92 ± 19 258 ± 76 0.02 
AUC (0→∞) (min*µg/ml) 429 ± 114 672 ± 51 0.06 
AUC (0→480) (min*µg/ml) 367 ± 88 440 ± 33 0.50 
Clearance (ml/min/kg) 14 ± 2   7.5 ± 0.6 0.06 
Tolbutamide 
Terminal half-life (min) 197 ± 37 321 ± 25 0.03 
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Supplementary Table 5: Summary of pharmacokinetic data on drugs administered orally to HBN and wild-type controls. 
Adult male HBN and WT mice (n =4) were administered a drug cocktail orally; serial blood samples were collected over a 8 hour 
period and analysed for plasma drug concentrations by LC-MS/MS and key pharmacokinetic parameters calculated. For the single 
dose tolbutamide, n = 2 for WT mice and n= 4 for HBN, therefore precluding statistical analysis of the data. 
Drug PK parameter WT HBN p-value 
AUC (0→∞) (min*µg/ml) 34 ± 3 124 ± 7 <0.001 
AUC (0→360) (min*µg/ml) 30 ± 1             120 ± 6 <0.001 
Cmax (µg/ml) 0.40 ± 0.03        1 ± 0.03 <0.001 
Clearance (ml/min/kg) 149 ± 12 41 ± 2 <0.001 
Midazolam 
Terminal half-life (min) 167 ± 58 70 ± 8 0.17 
Phenacetin AUC (0→∞) (min*µg/ml) 2.9 ± 0.4  4.9 ± 0.4 0.03 
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AUC (0→240) (min*µg/ml) 1.5 ± 0.1 1.8 ± 0.1 0.06 
Cmax (µg/ml) 0.06 ± 0.01 0.09 ± 0.02 0.02 
Clearance (ml/min/kg) 688 ± 30 550 ± 38 0.05 
 
Terminal half-life (min) 308 ± 44 279 ± 11 0.55 
AUC (0→∞) (min*µg/ml) 0.20 ± 0.07 0.22 ± 0.04 0.80 
AUC (0→240) (min*µg/ml) 0.11 ± 0.02 0.16 ± 0.03 0.23 
Cmax (ng/ml) 1.1 ± 0.1 1.5 ± 0.2 0.09 
Clearance (L/min/kg) 13 ± 4 9.5 ± 1.6 0.51 
Metoprolol 
Terminal half-life (min) 168 ± 51 130 ± 8 0.50 
AUC (0→∞) (min*µg/ml) 16 ± 2 13 ± 3 0.44 Chlorzoxazone 
AUC (0→360) (min*µg/ml) 15 ± 3 13 ± 3 0.57 
19 
 
Cmax (µg/ml) 0.37 ± 0.05 0.20 ± 0.02 0.06 
Clearance (ml/min/kg) 323 ± 42 425 ± 83 0.33 
 
Terminal half-life (min) 194 ± 31 46 ± 4 0.01 
AUC (0→∞) (min*µg/ml) 409 ± 58 315 ± 47 0.1 
AUC (0→480) (min*µg/ml) 249 ± 35             126 ± 9 0.02 
Cmax (µg/ml) 0.89 ± 0.12            0.34 ± 0.02 0.003 
Clearance (ml/min/kg) 13 ± 2 17 ± 2 0.14 
Tolbutamide (cocktail) 
Terminal half-life (min) 364 ± 33 640 ± 105 0.08 
AUC (0→∞) (min*µg/ml) 658 ± 269 907 ± 146 - Tolbutamide (single) 
AUC (0→480) (min*µg/ml) 344 ± 5 587 ± 47 - 
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Cmax (µg/ml) 1.4 ± 0.1 2.0 ± 0.2 - 
Clearance (ml/min/kg) 9.1 ± 3.7 6.1 ± 1.2 - 
 
Terminal half-life (min) 408 ± 249 286 ± 50 - 
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